Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features

Cancer

Volumn 107, Issue 1, 2006, Pages 154-161

  Osoegawa, Atsushi ^a,b   Yoshino, Ichiro ^a   Kometani, Takuro ^a   Yamaguchi, Masafumi ^a   Kameyama, Toshifumi ^a   Yohena, Tomofumi ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

Activator protein 1; Cyclin dependant kinase; Macrophage migration inhibitory factor; Nonsmall cell lung cancer; p27; S phase kinase interacting protein 2

Indexed keywords

CYCLIN DEPENDENT KINASE; JUN ACTIVATION DOMAIN BINDING PROTEIN 1; MACROPHAGE MIGRATION INHIBITION FACTOR; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SMOKING; STATISTICAL ANALYSIS; SURVIVAL RATE; TRANSACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JAPAN; MALE; MIDDLE AGED; PEPTIDE HYDROLASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; S-PHASE KINASE-ASSOCIATED PROTEINS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 33745309536     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21961     Document Type: Article

References (35)

1. Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
2. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351-360.
3. Lloyd RV, Erickson LA, Jin L, et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol. 1999;154:313-323.
4. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol. 2000;183:10-17.
5. Catzavelos C, Tsao MS, DeBoer G, et al. Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res. 1999;59:684-688.
6. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997;57:3381-3385.
7. Tsukamoto S, Sugio K, Sakada T, et al. Reduced expression of cell-cycle regulator p27(Kip1) correlates with a shortened survival in non-small cell lung cancer. Lung Cancer. 2001;34:83-90.
8. Pagano M, Tam S, Theodoras A, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 1995;269:682-685.
9. Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med. 2002;8:1153-1160.
10. Claret FX, Hibi M, Dhut S, et al. A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature. 1996;383:453-457.
11. Tomoda K, Kubota Y, Kato J. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature. 1999;398:160-165.
12. Korbonits M, Chahal HS, Kaltsas G, et al. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab. 2002;87:2635-2643.
13. Rassidakis GZ, Claret FX, Lai R, et al. Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma. Clin Cancer Res. 2003;9:1121-1128.
14. Sui L, Dong Y, Ohno M, et al. Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors. Clin Cancer Res. 2001;7:4130-4135.
15. Kouvaraki MA, Rassidakis GZ, Tian L, et al. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Res. 2003;63:2977-2981.
16. Shintani S, Li C, Mihara M, et al. Skp2 and Jab1 expression are associated with inverse expression of p27(KIP1) and poor prognosis in oral squamous cell carcinomas. Oncology. 2003;65:355-362.
17. Osoegawa A, Yoshino I, Tanaka S, et al. Regulation of p27 by S-phase kinase-associated protein 2 is associated with aggressiveness in non-small-cell lung cancer. J Clin Oncol. 2004;22:4165-4173.
18. World Health Organization. Histological Typing of Lung and Pleural Tumours. 3rd ed. Geneva: Springer-Verlag, 1999.
19. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710-1717.
20. Guo Y, Sklar GN, Borkowski A, Kyprianou N. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res. 1997;3:2269-2274.
21. Yatabe Y, Masuda A, Koshikawa T, et al. p27Kip1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res. 1998;58:1042-1047.
22. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999;155:1985-1992.
23. Goto A, Niki T, Moriyama S, et al. Immunohistochemical study of Skp2 and Jab1, two key molecules in the degradation of P27, in lung adenocarcinoma. Pathol Int. 2004;54:675-681.
24. Tomoda K, Yoneda-Kato N, Fukumoto A, et al. Multiple functions of Jab1 are required for early embryonic development and growth potential in mice. J Biol Chem. 2004;279:43013-43018.
25. Caballero OL, Resto V, Patturajan M, et al. Interaction and colocalization of PGP9.5 with JAB1 and p27(Kip1). Oncogene. 2002;21:3003-3010.
26. Kamura T, Hara T, Matsumoto M, et al. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat Cell Biol. 2004;6:1229-1235.
27. Ishida N, Hara T, Kamura T, et al. Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem. 2002;277:14355-14358.
28. Chopra S, Fernandez De Mattos S, Lam EW, et al. Jab1 co-activation of c-Jun is abrogated by the serine 10-phosphorylated form of p27Kip1. J Biol Chem. 2002;277:32413-32416.
29. Cope GA, Suh GS, Aravind L, et al. Role of predicted metalloprotease motif of Jab1/Csn5 in cleavage of Nedd8 from Cul1. Science. 2002;298:608-611.
30. Chauchercau A, Georgiakaki M, Purrin-Wolff M, et al. JAB1 interacts with both the progesterone receptor and SRC-1. J Biol Chem. 2000;275:8540-8548.
31. Kleemann R, Hausser A, Geiger G, et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature. 2000;408:211-216.
32. Bianchi K, Denti S, Granata A, et al. Integrin LFA-1 interacts with the transcriptional co-activator JAB1 to modulate AP-1 activity. Nature. 2000;404:617-621.
33. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat Rev Cancer. 2004;4:106-117.
34. Ossareh-Nazari B, Bachelerie F, Dargemont C. Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science. 1997;278:141-144.
35. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer. 1996;74:648-649.